In addition to maximizing the efficiency of its own research organization, GC Pharma has also been generating significant R&D synergy and open innovation through active exchange and collaboration with academia, innovative biotechnology startups, and leading global pharmaceutical companies. GC Pharma’s partners in and outside Korea continue to give the company an edge over its technological competition on the global biotechnology market and enable it to reinforce its R&D pipeline.
GC Pharma continues to seek to work with companies experienced in researching and developing biological products, including vaccines, plasma derivatives, and recombinant proteins; companies possessing infrastructure to support biological product research; companies committed to developing products for in-licensing; and companies with experience and capabilities in commercializing in-licensed products.
GC Pharma has extensive experience with the R&D of biological agents, such as vaccines, plasma derivatives, and recombinant proteins, employs professional R&D resources and possesses the capabilities for licensing, clinical trials, and business relations concerning such products. Throughout-licensing, GC Pharma allows its partners to access the expertise of the company’s R&D and clinical trial divisions as well as its competitive products. Under its mid- to long-term global growth strategy, GC Pharma is actively looking for potential opportunities for partnership over the products and technologies it is researching/developing or has already released on the market.